Intercept to Announce Fourth Quarter and Full Year 2020 Financial Results on February 25, 2021
The conference call will be available on the investor page of our website at http://ir.interceptpharma.com or by calling (855) 232-3919 (toll-free domestic) or (315) 625-6894 (international) passcode 7565656. Archived webcasts will be available on Intercept’s website for approximately two weeks.
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH). Founded in 2002 in
For more information about Intercept, please contact:
Investor inquiries: email@example.com
Media inquiries: firstname.lastname@example.org
Source: Intercept Pharmaceuticals, Inc.